← All themes

Immunotherapy & Oncology

Cancer treatment has moved from poisoning dividing cells towards directing the immune system at the tumour, and towards drugs that carry their payload only to cancerous tissue. It absorbs more drug development spending than any other area.

388 stocks

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Johnson & Johnson JNJ $612B	2,599	-25	-1%	$231B
2	2 Pfizer PFE $166B	2,231	-13	-0.6%	$150B
3	3 AbbVie ABBV $501B	2,016	+15	+0.7%	$106B
4	4 Merck MRK $364B	1,993	-16	-0.8%	$109B
5	5 Amgen AMGN $230B	1,750	+15	+0.9%	$89.8B
6	6 Bristol-Myers Squibb BMY $121B	1,747	+11	+0.6%	$74.9B
7	7 Gilead Sciences GILD $190B	1,565	-11	-0.7%	$77.3B
8	8 Novartis NVS $279B	1,013	+6	+0.6%	$20.7B
9	9 GSK GSK $95.9B	779	+15	+2%	$10.8B
10	10 Regeneron Pharmaceuticals REGN $80.1B	620	-19	-3%	$24.9B
11	11 AstraZeneca AZN $251B	520	+16	+3%	$13.9B
12	12 Incyte INCY $22.6B	500	-3	-0.6%	$16.5B
13	13 Jazz Pharmaceuticals JAZZ $13.6B	323	0	0%	$8.11B
14	14 DELISTED Exact Sciences EXAS	319	+1	+0.3%	$4.41B
15	15 Exelixis EXEL $15.1B	295	-7	-2%	$5.18B
16	SGEN 16 DELISTED Seagen Inc. Common Stock SGEN	287	-11	-4%	$8.67B
17	17 Myriad Genetics MYGN $397M	260	+10	+4%	$2.22B
18	18 Qiagen QGEN $9.41B	231	+16	+7%	$4.6B
19	CLVS 19 DELISTED Clovis Oncology, Inc. CLVS	229	-18	-7%	$2.63B
20	20 Opko Health OPK $1.02B	227	-5	-2%	$437M
21	21 Halozyme HALO $13.3B	209	+11	+6%	$2.42B
22	22 DELISTED Immunogen Inc IMGN	204	+4	+2%	$1.1B
23	23 Kyntra Bio KYNB $22.5M	193	+6	+3%	$2.47B
24	24 Puma Biotechnology PBYI $527M	178	-25	-12%	$2.42B
25	25 DELISTED Blueprint Medicines BPMC	175	+5	+3%	$4B